EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 390 filers reported holding EXELIXIS INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,046,613 | +34.7% | 139,439 | +17.8% | 0.01% | +25.0% |
| Q2 2023 | $2,261,151 | -8.5% | 118,337 | -6.9% | 0.00% | -20.0% |
| Q1 2023 | $2,470,522 | +62.7% | 127,139 | +34.4% | 0.01% | +66.7% |
| Q4 2022 | $1,518,155 | +0.9% | 94,567 | -1.5% | 0.00% | 0.0% |
| Q3 2022 | $1,504,000 | -33.8% | 95,985 | -11.9% | 0.00% | -40.0% |
| Q2 2022 | $2,271,000 | +20.5% | 108,983 | +13.6% | 0.01% | +25.0% |
| Q1 2022 | $1,885,000 | +22.1% | 95,903 | +14.6% | 0.00% | +33.3% |
| Q4 2021 | $1,544,000 | +16.7% | 83,721 | +34.4% | 0.00% | 0.0% |
| Q3 2021 | $1,323,000 | +20.7% | 62,293 | +3.9% | 0.00% | +50.0% |
| Q2 2021 | $1,096,000 | -16.8% | 59,955 | +3.3% | 0.00% | -33.3% |
| Q1 2021 | $1,317,000 | +5.2% | 58,023 | -7.0% | 0.00% | 0.0% |
| Q4 2020 | $1,252,000 | -16.4% | 62,390 | +1.3% | 0.00% | -25.0% |
| Q3 2020 | $1,498,000 | -2.7% | 61,575 | -5.0% | 0.00% | -20.0% |
| Q2 2020 | $1,540,000 | -11.5% | 64,841 | -35.7% | 0.01% | -28.6% |
| Q1 2020 | $1,741,000 | – | 100,807 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |